P1/2, N=21, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2021 | Trial primary completion date: Dec 2023 --> Mar 2021
3 years ago
Clinical • Trial completion • Trial completion date • Trial primary completion date
|
GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • MAGEA3 (MAGE Family Member A3)
|
fludarabine IV • Proleukin (aldesleukin) • MAGE A3 TCR